TPCA-1 is a direct dual inhibitor of STAT3 and NF-κB and regresses mutant EGFR-associated human non-small cell lung cancers

Molecular Cancer Therapeutics

Volumn 13, Issue 3, 2014, Pages 617-629

  Nan, Jing ^a   Du, Yuping ^a   Chen, Xing ^a   Bai, Qifeng ^a   Wang, Yuxin ^a   Zhang, Xinxin ^a   Zhu, Ning ^a   Zhang, Jing ^a   Hou, Jianwen ^a   Wang, Qin ^a   Yang, Jinbo ^a,b  

^a LANZHOU UNIVERSITY   (China)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 (4 METHYLPHENYLSULFONYL) 2 PROPENENITRILE; ANTINEOPLASTIC AGENT; CYCLOOXYGENASE 2; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; METHYLCELLULOSE; PROTEIN SH2; STAT3 PROTEIN; TPCA 1; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CELL CULTURE; CELL PROLIFERATION; CELL VIABILITY ASSAY; CONTROLLED STUDY; DNA BINDING; FEMALE; FLOW CYTOMETRY; IMMUNOCYTOCHEMISTRY; IN VIVO STUDY; LUCIFERASE ASSAY; LUNG NON SMALL CELL CANCER; MOLECULAR MODEL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RADIOIMMUNOPRECIPITATION; REAL TIME POLYMERASE CHAIN REACTION; TARGET CELL; TRANSACTIVATION; WESTERN BLOTTING;

AMIDES; APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; I-KAPPA B PROTEINS; MUTATION; NF-KAPPA B; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; THIOPHENES;

EID: 84896304299     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-13-0464     Document Type: Article

References (47)

1. Karin M. Nuclear factor-κB in cancer development and progression. Nature 2006;441:431-6. (Pubitemid 44050137)
2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA: Cancer J Clin 2009;59:225-49.
3. Cataldo VD, Gibbons DL, Perez-Soler R, Quintas-Cardama A. Treatment of non-small-cell lung cancer with erlotinib or gefitinib. N Engl J Med 2011;364:947-55.
4. Herbst RS, Heymach JV, Lippman SM. Lung cancer. N Engl J Med 2008;359:1367-80.
5. Sequist LV, Bell DW, Lynch TJ, Haber DA. Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer. J Clin Oncol 2007;25:587-95. (Pubitemid 350002967)
6. Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010;362:2380-8.
7. Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small- cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010;11:121-8.
8. Chang A, Parikh P, Thongprasert S, Tan EH, Perng R-P, Ganzon D, et al. Gefitinib (IRESSA) in patients of Asian origin with refractory advanced non-small cell lung cancer: subset analysis from the ISEL study. J Thorac Oncol 2006;1:847-55. (Pubitemid 47181391)
9. Inoue A, Suzuki T, Fukuhara T, Maemondo M, Kimura Y, Morikawa N, et al. Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small cell lung cancer with epidermal growth factor receptor gene mutations. J Clin Oncol 2006;24:3340-6. (Pubitemid 46638887)
10. Yoshida K, Yatabe Y, Park JY, Shimizu J, Horio Y, Matsuo K, et al. Prospective validation for prediction of gefitinib sensitivity by epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer. J Thorac Oncol 2007;2:22-8. (Pubitemid 47163924)
11. Bowman T, Garcia R, Turkson J, Jove R. STATs in oncogenesis. Oncogene 2000;19:2474-88. (Pubitemid 30339203)
12. Leaman DW, Leung S, Li X, Stark G. Regulation of STAT-dependent pathways by growth factors and cytokines. FASEB J 1996;10:1578-88. (Pubitemid 27043774)
13. Darnell JE Jr, Kerr IM, Stark GR. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 1994;264:1415-20.
14. Silva CM. Role of STATs as downstream signal transducers in Src family kinase-mediated tumorigenesis. Oncogene 2004;23:8017-23. (Pubitemid 39468859)
15. Seki Y, Suzuki N, Imaizumi M, Iwamoto T, Usami N, Ueda Y, et al. STAT3 and MAPK in human lung cancer tissues and suppression of oncogenic growth by JAB and dominant negative STAT3. Int J Oncol 2004;24:931-4.
16. Mukohara T, Kudoh S, Yamauchi S, Kimura T, Yoshimura N, Kanazawa H, et al. Expression of epidermal growth factor receptor (EGFR) and downstream-activated peptides in surgically excised non-small cell lung cancer (NSCLC). Lung Cancer 2003;41:123-30. (Pubitemid 36842775)
17. Sordella R, Bell DW, Haber DA, Settleman J. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Sci Signal 2004;305:1163.
18. Alvarez JV, Greulich H, Sellers WR, Meyerson M, Frank DA. Signal transducer and activator of transcription 3 is required for the oncogenic effects of non-small cell lung cancer-associated mutations of the epidermal growth factor receptor. Cancer Res 2006;66:3162-8.
19. Gao SP, Mark KG, Leslie K, Pao W, Motoi N, Gerald WL, et al. Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas. J Clin Invest 2007;117:3846-56. (Pubitemid 350224094)
20. Haura EB, Livingston S, Coppola D. Autocrine interleukin-6/interleukin-6 receptor stimulation in non-small-cell lung cancer. Clin Lung Cancer 2006;7:273-5. (Pubitemid 43280031)
21. Sansone P, Storci G, Tavolari S, Guarnieri T, Giovannini C, Taffurelli M, et al. IL-6 triggers malignant features in mammospheres from human ductal breast carcinoma and normal mammary gland. J Clin Invest 2007;117:3988-4002. (Pubitemid 350224108)
22. Karin M, Ben-Neriah Y. Phosphorylation meets ubiquitination: the control of NF-κB activity. Annu Rev Immunol 2000;18:621-63. (Pubitemid 30365393)
23. Senftleben U, Cao Y, Xiao G, Greten FR, Krahn G, Bonizzi G, et al. Activation by IKKα of a second, evolutionary conserved, NF-κB signaling pathway. Sci Signal 2001;293:1495-9. (Pubitemid 32801552)
24. Tanaka K, Babic I, Nathanson D, Akhavan D, Guo D, Gini B, et al. Oncogenic EGFR signaling activates an mTORC2-NF-κB pathway that promotes chemotherapy resistance. Cancer Discov 2011;1:524-38.
25. Sethi G, Ahn K, Chaturvedi M, Aggarwal B. Epidermal growth factor (EGF) activates nuclear factor-κB through IκBα kinase-independent but EGF receptor-kinase dependent tyrosine 42 phosphorylation of IκBα. Oncogene 2007;26:7324-32. (Pubitemid 350115978)
26. Tang X, Liu D, Shishodia S, Ozburn N, Behrens C, Lee JJ, et al. Nuclear factor-κB (NF-κB) is frequently expressed in lung cancer and preneoplastic lesions. Cancer 2006;107:2637-46. (Pubitemid 44845619)
27. Bivona TG, Hieronymus H, Parker J, Chang K, Taron M, Rosell R, et al. FAS and NF-κB signalling modulate dependence of lung cancers on mutant EGFR. Nature 2011;471:523-6.
28. Podolin PL, Callahan JF, Bolognese BJ, Li YH, Carlson K, Davis TG, et al. Attenuation of murine collagen-induced arthritis by a novel, potent, selective small molecule inhibitor of IκB kinase 2, TPCA-1 (2-[(aminocarbonyl) amino]-5-(4-fluorophenyl)-3-thiophenecarboxamide), occurs via reduction of proinflammatory cytokines and antigen-induced T cell proliferation. J Pharmacol Exp Ther 2005;312:373-81. (Pubitemid 40096491)
29. Pierce JW, Schoenleber R, Jesmok G, Best J, Moore SA, Collins T, et al. Novel inhibitors of cytokine-induced IκBα phosphorylation and endothelial cell adhesion molecule expression show anti-inflammatory effects in vivo. J Biol Chem 1997;272:21096-103. (Pubitemid 27373968)
30. Saez-Rodriguez J, Alexopoulos LG, Zhang M, Morris MK, Lauffenburger DA, Sorger PK. Comparing signaling networks between normal and transformed hepatocytes using discrete logical models. Cancer Res 2011;71:5400-11.
31. Su L, David M. Distinct mechanisms of STAT phosphorylation via the interferon-α/β receptor. Selective inhibition of STAT3 and STAT5 by piceatannol. Sci Signal 2000;275:12661-6. (Pubitemid 30241415)
32. Shao H, Cheng HY, Cook RG, Tweardy DJ. Identification and characterization of signal transducer and activator of transcription 3 recruitment sites within the epidermal growth factor receptor. Cancer Res 2003;63:3923-30. (Pubitemid 36917907)
33. Xu X, Kasembeli MM, Jiang X, Tweardy BJ, Tweardy DJ. Chemical probes that competitively and selectively inhibit Stat3 activation. PLoS ONE 2009;4:e4783.
34. Song H, Wang R, Wang S, Lin J. A low-molecular-weight compound discovered through virtual database screening inhibits Stat3 function in breast cancer cells. Proc Natl Acad Sci U S A 2005;102:4700-5. (Pubitemid 40471517)
35. Siddiquee K, Zhang S, Guida WC, Blaskovich MA, Greedy B, Lawrence HR, et al. Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity. Proc Natl Acad Sci 2007;104:7391-6. (Pubitemid 47185916)
36. Sanner MF. Python: a programming language for software integration and development. J Mol Graph Model 1999;17:57-61. (Pubitemid 30029318)
37. Song L, Rawal B, Nemeth JA, Haura EB. JAK1 activates STAT3 activity in non -small cell lung cancer cells and IL-6 neutralizing antibodies can suppress JAK1-STAT3 signaling. Mol Cancer Ther 2011;10:481-94.
38. Narayan C, Kumar A. Constitutive over expression of IL-1β, IL-6, NF-κB, and Stat3 is a potential cause of lung tumorigenesis in urethane (ethyl carbamate) induced Balb/c mice. J Carcinog 2012;11:9.
39. Hida T, Yatabe Y, Achiwa H, Muramatsu H, Kozaki K-i, Nakamura S, et al. Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas. Cancer Res 1998;58:3761-4. (Pubitemid 28405625)
40. Grivennikov SI, Karin M. Dangerous liaisons: STAT3 and NF-κB collaboration and crosstalk in cancer. Cytokine Growth Factor Rev 2010;21:11-9.
41. Kim SM, Kwon O-J, Hong YK, Kim JH, Solca F, Ha S-J, et al. Activation of IL-6R/JAK1/STAT3 signaling induces de novo resistance to irreversible EGFR inhibitors in non-small cell lung cancer with T790M resistance mutation. Mol Cancer Ther 2012;11:2254-64.
42. Alberti C, Pinciroli P, Valeri B, Ferri R, Ditto A, Umezawa K, et al. Ligand-dependent EGFR activation induces the co-expression of IL-6 and PAI-1 via the NF-κB pathway in advanced-stage epithelial ovarian cancer. Oncogene 2011;31:4139-49.
43. Brandi G, Pantaleo MA, Biasco G, Paterini P. Activated NF-κB in colorectal cancer: predictive or prognostic factor? J Clin Oncol 2008;26:1388-9.
44. Hong SH, Ondrey FG, Avis IM, Chen Z, Loukinova E, Cavanaugh PF, et al. Cyclooxygenase regulates human oropharyngeal carcinomas via the proinflammatory cytokine IL-6: a general role for inflammation? FASEB J 2000;14:1499-507. (Pubitemid 30636555)
45. Dalwadi H, Krysan K, Heuze-Vourc'h N, Dohadwala M, Elashoff D, Sharma S, et al. Cyclooxygenase-2-dependent activation of signal transducer and activator of transcription 3 by interleukin-6 in non-small cell lung cancer. Clin Cancer Res 2005;11:7674-82. (Pubitemid 41611609)
46. Gadgeel SM, Ali S, Philip PA, Ahmed F, Wozniak A, Sarkar FH. Response to dual blockade of epidermal growth factor receptor (EGFR) and cycloxygenase 2 in non-small cell lung cancer may be dependent on the EGFR mutational status of the tumor. Cancer 2007;110:2775-84. (Pubitemid 350250349)
47. Sequist LV, Waltman BA, Dias-Santagata D, Digumarthy S, Turke AB, Fidias P, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 2011;3:75ra26.